Navigation Links
Technology targets genetic disorders linked to X chromosome
Date:10/18/2011

Geneticists at Emory University School of Medicine have demonstrated a method that enables the routine amplification of all the genes on the X chromosome. The technology allows the rapid and highly accurate sequencing and identification of novel genetic variants affecting X chromosome genes.

The method, developed in cooperation with RainDance Technologies (www.RainDanceTech.com), is described in the Oct. 2011 issue of Genomics. Senior author Michael Zwick, PhD, assistant professor of human genetics at Emory University School of Medicine, is using the method to identify genetic variants that contribute to autism spectrum disorders.

Because the X chromosome is a hotspot for genes that are suspected of contributing to autism and intellectual disability, the Emory team's finding could speed new discoveries and eventually make routine clinical diagnosis of autism and intellectual disability easier.

"This technology has the potential to be a valuable tool for genetic researchers across a wide variety of applications," Zwick says. "Our data shows that it can support the routine sequencing of the exons of the human X chromosome in a uniform, accurate and comprehensive way."

The team's sequencing method does not read all the letters of the genetic code in the X chromosome from beginning to end. Instead, it targets more than 800 "exons": all the genes that get read out and made into RNA.

A direct comparison with another method of target selection called oligonucleotide capture showed that the team's technique needed between three and seven times fewer sequence reads to achieve high levels of accuracy and completeness, potentially meaning lower costs.

The Emory team's experiments showed that their technique could read 97 percent of targeted sequences at high depth with an accuracy of 99.5 percent. The team used data from the HapMap Project, a partnership coordinated by the Human Genome Research Institute, as a reference standard for genetic sequence variation.

Sex is determined by having two X chromosomes (female) or an X and a Y chromosome (male). Because males have only a single X chromosome, a mutation in a gene on the X chromosome is more likely to affect a male than a female because males lack another copy of the same gene to compensate. This pattern of inheritance can contribute to disorders that disproportionately affect males, such as autism spectrum disorder or intellectual disability.

Modern DNA sequencing techniques use the polymerase chain reaction (PCR) to isolate and "amplify" the target DNA scientists want to read. RainDance Technologies has developed a single molecule microdroplet-based technology that enables scientists to target up to 20,000 genomic loci in a single sample, saving time, space and cost while increasing reliability and ease of use. The reactions take place in millions of self-contained droplets, allowing each to amplify a different piece of DNA within an emulsion.


'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Related biology news :

1. New method of growing high-quality graphene promising for next-gen technology
2. Roche licenses DNA sequencing technology from Biodesign Institute
3. Hear live webcast tonight of top NJIT awardee detailing future of nanotechnology
4. Rutgers-affiliated company receives funding for technology to help choose breast cancer treatments
5. Thin - Film Photovoltaic (PV) Cells Market Analysis to 2020 - CIGS (Copper Indium Gallium Diselenide) to Emerge as the Major Technology by 2020
6. For common toy breed dog windpipe issue, MU veterinarians use technology and precision
7. New technology offers the next generation of mammography
8. Card Logistics to Auction Smart Card Gaming Technology at Upcoming ICAP Patent Brokerage Fall 2011 Live IP Auction in San Francisco
9. Rice wins grant to develop CO2 capture technology
10. SuviCa Inc. of Boulder to commercialize CU-Boulder cancer screening technology
11. Purdue technology used in first fluorescence-guided ovarian cancer surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake Lubinski, describes ... characteristics when deformed, which is identical to how the human discs work to ... and return to its natural state along a hysteresis curve, exactly like a ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
Breaking Biology Technology: